Chimerix (CMRX) News Today

Chimerix (NASDAQ:CMRX) Share Price Crosses Below Two Hundred Day Moving Average of $0.97

Chimerix, Inc. (NASDAQ:CMRX - Get Free Report) was the recipient of a large drop in short interest during the month of August. As of August 15th, there was short interest totalling 1,690,000 shares, a drop of 10.6% from the July 31st total of 1,890,000 shares. Approximately 2.1% of the shares of the company are short sold. Based on an average daily volume of 485,300 shares, the days-to-cover ratio is currently 3.5 days.

Chimerix, Inc. (NASDAQ:CMRX - Get Free Report) was the target of a significant increase in short interest in July. As of July 31st, there was short interest totalling 1,890,000 shares, an increase of 18.1% from the July 15th total of 1,600,000 shares. Based on an average daily volume of 213,100 shares, the days-to-cover ratio is presently 8.9 days. Currently, 2.4% of the company's stock are short sold.

Chimerix, Inc. (NASDAQ:CMRX - Free Report) - Stock analysts at Wedbush dropped their Q1 2025 earnings estimates for Chimerix in a note issued to investors on Tuesday, August 13th. Wedbush analyst D. Nierengarten now expects that the biopharmaceutical company will post earnings of ($0.24) per shar

Chimerix, Inc. (NASDAQ:CMRX - Free Report) - Equities researchers at Capital One Financial reduced their FY2028 EPS estimates for shares of Chimerix in a research note issued on Tuesday, August 13th. Capital One Financial analyst N. Quibria now forecasts that the biopharmaceutical company will ea

HC Wainwright restated a "buy" rating and set a $11.00 target price on shares of Chimerix in a report on Wednesday.

Chimerix (NASDAQ:CMRX - Get Free Report) posted its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.23). Chimerix had a negative net margin of 25,337.96% and a negative return on equity of 41.32%. The business had revenue of $0.13 million for the quarter, compared to analyst estimates of $1.26 million. During the same quarter last year, the business posted ($0.21) EPS.

Wedbush restated an "outperform" rating and set a $6.00 target price on shares of Chimerix in a research report on Tuesday.

Chimerix (NASDAQ:CMRX) will be releasing earnings before the market opens on Tuesday, August 13, Zacks reports.

Chimerix (NASDAQ:CMRX) Stock Price Crosses Below 200-Day Moving Average of $0.99

Chimerix (NASDAQ:CMRX) Stock Crosses Below 200 Day Moving Average of $0.99

Chimerix (NASDAQ:CMRX) Share Price Crosses Below Two Hundred Day Moving Average of $0.99

Vestal Point Capital LP bought a new stake in Chimerix, Inc. (NASDAQ:CMRX - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 1,400,000 shares of the biopharmaceutical company's stock, valued at approxima

StockNews.com raised Chimerix from a "sell" rating to a "hold" rating in a research report on Saturday.

Chimerix, Inc. (NASDAQ:CMRX - Get Free Report) was the target of a significant drop in short interest during the month of May. As of May 15th, there was short interest totalling 1,280,000 shares, a drop of 5.9% from the April 30th total of 1,360,000 shares. Based on an average trading volume of 338,000 shares, the short-interest ratio is currently 3.8 days. Approximately 1.6% of the company's shares are sold short.

StockNews.com upgraded shares of Chimerix from a "sell" rating to a "hold" rating in a research report on Wednesday.

StockNews.com cut Chimerix from a "hold" rating to a "sell" rating in a report on Friday.

Chimerix, Inc. (NASDAQ:CMRX - Free Report) - Equities research analysts at Capital One Financial reduced their FY2028 earnings per share estimates for shares of Chimerix in a research report issued on Wednesday, May 1st. Capital One Financial analyst N. Quibria now anticipates that the biopharmac

Chimerix (NASDAQ:CMRX - Get Free Report) issued its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.04). Chimerix had a negative net margin of 25,337.96% and a negative return on equity of 37.93%. During the same quarter in the previous year, the firm posted ($0.24) EPS.

Chimerix (NASDAQ:CMRX) will be releasing earnings before the market opens on Wednesday, May 1, Zacks reports.